surpass 2 tirzepatide Read now: The SURPASS-EARLY trial found that starting #tirzepatide early in #type2diabetes led to greater improvements in blood sugar, body weight, and waist size than intensified standard care. https://bit.ly/3RWnB8m Time to Reach Glycaemic and
Description
In the SURMOUNT-5 head-to-head trial, Zepbound (tirzepatide) produced more weight loss than Wegovy (semaglutide) on average: 20.2% versus 13.7%

Additionally, Novo Nordisk has decided to partner with Hims & Hers as announced in April and Eli Lilly is partnering with Ro on Zepbound as announced in December

some patients benefit from auto-ship reminders or calendar alerts to prevent lapses
M.BeaudinM.WibowoM

The effect of glucagon like peptide-1 receptor agonist on behavioral despair and anxiety-like behavior in ovariectomized rats: Modulation of BDNF/CREB, Nrf2 and lipocalin 2
Energy and Focus: Managing weight can sometimes come with dips in energy
